NEFECON receives Chinese approval for expanded IgA nephropathy treatment
China’s National Medical Products Administration has approved expanded production capacity for NEFECON®, the only etiological treatment for IgA nephropathy. The regulatory milestone addresses growing clinical demand across Asia, where over 5 million patients live with this progressive kidney disease requiring targeted therapeutic intervention.
